The Institute of Medicine will weigh in on the knotty issue of clinical trial data sharing when it releases its preliminary guiding principles Wednesday. Experts hope they will address key concerns facing academic researchers and manufacturers, including increasing transparency to build public trust in research results.
Access to data traditionally has been considered proprietary. Scientists attempting to review small, often unpublished, studies, especially those from the pharmaceutical industry, have not been able to gain access to the data. But efforts to make data more readily available have been growing.